文献速递肝胆胰外科围术期管理与 ERAS

新辅助治疗在衰弱胰腺癌患者中的手术安全性与结局影响

Neoadjuvant therapy in frail patients with pancreatic cancer: Impact on surgical safety and outcomes.
PubMed 文献 · Surgery · 2026-04-20

基于美国外科医师学会NSQIP胰腺切除数据库2014-2023年数据,纳入29528例胰腺导管腺癌切除患者,其中24.59%为衰弱患者。衰弱与接受新辅助治疗几率降低相关(OR 0.881,P<.001),但在最终手术的衰弱患者中,新辅助治疗与术后30天多种并发症风险降低独立相关。衰弱本身不应被视为新辅助治疗的禁忌证。

要点

  • 衰弱与接受新辅助治疗几率降低相关(OR 0.881,P<.001)。
  • 衰弱患者中新辅助治疗与延迟性胃排空、呼吸事件、感染并发症等风险降低相关。
  • 衰弱未显著改变新辅助治疗效应,但衰弱患者心脏骤停获益可能更大。

核心结论

  • 衰弱本身不应被视为新辅助治疗的禁忌证,最终手术的衰弱患者围术期风险可控。

研究设计与样本

  • 回顾性队列研究,使用美国外科医师学会NSQIP胰腺切除靶向数据库2014-2023年数据。
  • 纳入29528例接受胰十二指肠切除术或远端胰腺切除术的胰腺导管腺癌患者。
  • 衰弱定义为改良5因子衰弱指数评分≥2。

主要发现

  • 29528例患者中7261例(24.59%)为衰弱,11235例(38.05%)接受新辅助治疗。
  • 衰弱与接受新辅助治疗几率降低相关(OR 0.881,P<.001)。
  • 衰弱患者中新辅助治疗与延迟性胃排空几率降低独立相关(OR 0.855,P=.034)。
  • 衰弱患者中新辅助治疗与经皮引流管放置(OR 0.744,P<.001)、术后30天手术引流管存在(OR 0.662,P<.001)、心脏骤停(OR 0.531,P=.010)、延长住院(OR 0.707,P=.036)几率降低相关。
  • 衰弱患者中新辅助治疗与呼吸事件、感染并发症风险降低相关(P<.05)。

关键数值与推荐

  • 衰弱定义为改良5因子衰弱指数评分≥2。
  • 交互分析显示衰弱未显著改变新辅助治疗效应,但衰弱患者心脏骤停获益可能更大。

临床怎么用

  • 对衰弱胰腺癌患者,不应仅因衰弱而排除新辅助治疗。
  • 衰弱患者接受新辅助治疗后若最终手术,围术期风险可管理。

局限性

  • 回顾性数据库研究,可能存在选择偏倚和混杂。
  • 仅纳入最终接受手术的患者,未反映未手术衰弱患者的情况。
  • 衰弱定义基于改良5因子指数,可能受数据库变量限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Frailty predicts poor outcomes after pancreatic resection, but its influence on the use, tolerability, and perioperative safety of neoadjuvant therapy among resected patients remains unclear. METHODS: Using the American College of Surgeons National Surgical Quality Improvement Program pancreatectomy-targeted database (2014-2023), we identified patients undergoing pancreatoduodenectomy or distal pancreatectomy for pancreatic ductal adenocarcinoma. Frailty was defined as a modified 5-factor frailty index score ≥2. Multivariable logistic regression evaluated the association between frailty and neoadjuvant therapy receipt and the effect of neoadjuvant therapy on 30-day outcomes in frail patients. Effect modification by frailty status was assessed by including an interaction term between frailty and neoadjuvant therapy. RESULTS: Among 29,528 patients, 7,261 (24.59%) were frail, and 11,235 (38.05%) received neoadjuvant therapy. Frailty was associated with decreased neoadjuvant therapy receipt (odds ratio, 0.881; P < .001). In multivariable analyses of frail patients, neoadjuvant therapy was independently associated with lower odds of delayed gastric emptying (odds ratio, 0.855; P = .034), percutaneous drain placement (odds ratio, 0.744; P < .001), operative drain present at postoperative day 30 (odds ratio, 0.662; P < .001), respiratory events (P < .05), infectious complications (P < .05), cardiac arrest (odds ratio, 0.531; P = .010), and prolonged hospitalization (odds ratio, 0.707; P = .036) when compared with upfront resection. Interaction analyses showed that frailty did not significantly modify neoadjuvant therapy effects; however, frail patients who underwent resection appeared to derive greater benefit regarding cardiac arrest. CONCLUSION: Frailty alone should not necessarily be considered a contraindication to neoadjuvant therapy. Among frail patients who ultimately proceed to resection, the perioperative risks of neoadjuvant therapy appear manageable.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Bitar ER, El Moheb M, Cummins KC, et al. Neoadjuvant therapy in frail patients with pancreatic cancer: Impact on surgical safety and outcomes. Surgery. 2026. PMID: 42114467. doi:10.1016/j.surg.2026.110256

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。